Product Datasheet and Instructions for Use Product Code: MP-323-CM01 (0.1ml conc) MP-323-CM05 (0.5ml conc) Product Description: CD24 Concentrated Monoclonal Antibody Control Number: 901-323-052510 ISO 9001:2000 CERTIFIED Summary and Explanation: Antigen detection, in tissues and cells, is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labelling the antigen with a primary antibody, a universal, affinity-purified, secondary antibody is added to bind to the primary antibody. An enzyme label is then added to bind to the secondary antibody; this detection of the bound antibody is evidenced by a colorimetric reaction.
CD24 (30-70kDa molecular weight) is a two chain glycosylphosphatidylinositol (GPI) -anchored glycoprotein. It is a mucin-like adhesion molecule. CD24 functionally enhances themetastatic potential of malignant-cells, as it has been also identified as a ligand of P-selectin,an adhesion receptor on activated endothelial cells and platelets. Research has shown CD24expression as a potentially significant parameter for a wide variety of human cancer diagnosisand for patient prognosis. Elevated CD24 membranous expression and, in particular,cytoplasmic staining seem to predict malignant transformation. Recent studies have shownCD24 as a prognostic marker for breast cancer and more specifically for tamoxifen-resistantbreast cancer cases. Further studies have shown a sub-population (CD44+/CD24-) of breastcancer cells reported to have stem/progenitor cell properties. Intended Use: For In Vitro Diagnostic Use Source: Mouse Monoclonal Species Reactivity: Human; others not tested Clone: SN3b Authorized Representative: Manufactured by: Distributed by: Isotype: IgM/kappa Total Protein Concentration: ~10 mg/ml. Call for lot specific Ig Concentration. Epitope/Antigen: CD24 Cellular Localization: Cytoplasmic and/or cell membrane Positive Control: Some breast cancers Normal Tissue: Skin and kidney Abnormal Tissue: Breast, ovarian or prostate cancer Known Applications: Immunohistochemistry (formalin-fixed paraffin-embedded tissues) Supplied As: Buffer with protein carrier and preservative. Storage and Stability: Store at 2ºC to 8ºC. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at 2ºC to 8ºC. Authorized Representative: Manufactured by: Distributed by: Instructions for Use: Endogenous Peroxidase Block Block all endogenous peroxidase activity by incubating the sections for 5 minutes with the MenaPath Peroxide Block. Rinse slides in water, and then rinse well in buffer. Pretreatment Protocol: Retrieve sections with MenaPath Access Supreme or Access Revelation Solution using the MenaPath Access Retrieval Unit at 80°C for 30 minutes followed by a wash in distilled water.
Alternatively, steam tissue sections for 45-60 minutes. Allow solution to cool for 20 minutesthen wash in distilled water. Protein Block Incubate sections for 10-15 minutes at room temperature with the MenaPath Background Blocker with Casein Primary Antibody Dilute antibody 1:100-1:200 with MenaPath Sensitivity Enhancing Antibody Diluent B. Incubate sections for 30 minutes at room temperature. Rinse slides x3 with buffer. Universal Probe Incubate sections for 10-20 minutes at room temperature with the MenaPath X-Cell Plus Universal Probe. Rinse slides x3 with buffer HRP Polymer Incubate sections for 10-25 minutes at room temperature with the MenaPath X-Cell Plus HRP Polymer. Rinse slides x3 in buffer. Chromogen Incubate sections for 5 minutes at room temperature with MenaPath X-Cell Plus Liquid Stable DAB. Rinse x3 with buffer. Counterstain: Incubate for 30-60 seconds with MenaPath Haematoxylin. Rinse with deionized water. Apply Bluing solution for 1 minute. Dehydrate, Clear and Mount Authorized Representative: Manufactured by: Distributed by: Technical Note: Use TBS buffer for wash steps. Performance Characteristics: The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to: fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of MenaPath products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. These products are tools that can be used for interpretation of morphological findings in conjunction with other diagnostic tests and pertinent clinical data by a qualified pathologist. Quality Control: Refer to NCCLS Quality Assurance for Immunocytochemistry approved guidelines, December 1999 MM4-A Vol.19 No.26 for more information about Tissue Controls. Precautions: This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN3) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for disease control, 1976, National Institute of Occupational Safety and Health, 1976) Specimens, before and after fixation and all materials exposed to them, should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water. Microbial contamination of reagents may result in an increase in nonspecific staining. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change. The MSDS is available upon request. Troubleshooting: Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Menarini's Technical Service Helpline: on 01189 444130. Authorized Representative: Manufactured by: Distributed by: Limitations and Warranty There are no warranties, expressed or implied, which extend beyond this description. Menarini is not liable for damages of any kind including: personal injury, or economic loss caused by this product. Reference: 1. Surowiak P et al. CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res. 2006 Jan-Feb;26(1B):629-34. 2. Baumann P et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005 Dec 1;65 (23):10783-93. 3. Dontu G, Liu S, Wicha MS. Stem cells in mammary development and carcinogenisis: implications for prevention and treatment. Stem Cell Rev. 2005;1 (3):207-13. 4. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts." 5. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious diseases transmitted by blood and tissue; proposed guideline. Villanova, PA 1991;7 (9). Order code M29-P. Authorized Representative: Manufactured by: Distributed by:
Schaltvorgänge der Transkription Friedrich-Alexander-Universität Erlangen-Nürnberg International Symposium Molecular Control of Gene Expression Invited speakers: Walter Birchmeier Berlin, Germany Richard G. Brennan Portland, USA Martin Eilers Marburg, Germany Roger D. Everett Glasgow, UK Hiroshi Handa Yokohama, Japan Wolfg
Eur J Clin PharmacolDOI 10.1007/s00228-007-0394-1Identification of severe potential drug-drug interactionsusing an Italian general-practitioner databaseL. Magro & A. Conforti & F. Del Zotti & R. Leone &M. L. Iorio & I. Meneghelli & D. Massignani & E. Visonà &U. MorettiReceived: 9 July 2007 / Accepted: 27 September 2007number of different types of severe potenti